(118) suggested that FOXO3 was an important target of methyltransferase-like 3-mediated m6A modification in the resistance of HCC to sorafenib therapy and could activate autophagy-associated signaling pathways. This evidence concerns the gene FOXO3 and hepatocellular carcinoma.